retatrutide phase 2 trial type 2 diabetes results 2024 ESC 2024: improves lipid and cardiovascular risk profile in II Retatrutide Phase 2: Type 2
Description
7038-00008B)
Ractions au site dinjection : rougeur, douleur, dmangeaisons
NutrMetab (Lond)
These symptoms typically emerge within the first few weeks of treatment or following dose increases
Less healthcare utilization for tobacco use disorder was also associated with this patient group
